Daniel Lesueur Sells 5,209 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.51, for a total value of $39,119.59. Following the transaction, the chief operating officer now owns 91,253 shares of the company’s stock, valued at $685,310.03. The trade was a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Daniel Lesueur also recently made the following trade(s):

• On Tuesday, November 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The shares were sold at an average price of $7.70, for a total transaction of $40,109.30.

Health Catalyst Stock Down 6.4 %

Shares of HCAT stock opened at $6.89 on Friday. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst, Inc. has a 12 month low of $5.42 and a 12 month high of $11.41. The stock has a market cap of $419.24 million, a P/E ratio of -5.10 and a beta of 1.36. The company has a 50 day simple moving average of $7.79 and a two-hundred day simple moving average of $7.53.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.22) earnings per share. On average, research analysts expect that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

HCAT has been the topic of a number of recent analyst reports. Evercore ISI increased their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Citigroup reduced their target price on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective for the company in a report on Wednesday. Finally, Stephens upped their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday, November 14th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.45.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in HCAT. First Light Asset Management LLC raised its position in shares of Health Catalyst by 438.5% during the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after purchasing an additional 3,221,408 shares during the period. Millennium Management LLC raised its holdings in Health Catalyst by 96.3% during the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after acquiring an additional 1,184,131 shares during the period. Nepsis Inc. lifted its position in shares of Health Catalyst by 67.9% in the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock valued at $17,131,000 after acquiring an additional 851,448 shares in the last quarter. Fred Alger Management LLC bought a new position in shares of Health Catalyst in the third quarter worth about $6,858,000. Finally, Portolan Capital Management LLC purchased a new stake in shares of Health Catalyst during the third quarter worth about $5,402,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.